Publicaciones en las que colabora con Diana Isabel Llopiz Khatchikian (12)

2017

  1. Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor

    Oncotarget, Vol. 8, Núm. 42, pp. 71709-71724

2015

  1. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

2013

  1. Helper cell-independent antitumor activity of potent CD8+ T cell epitope peptide vaccines is dependent upon CD40L

    OncoImmunology, Vol. 2, Núm. 12, pp. 1-11

2011

  1. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors

    Cancer Research, Vol. 71, Núm. 9, pp. 3214-3224

  2. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice

    Journal of Immunology, Vol. 185, Núm. 9, pp. 5150-5159

2009

  1. Peptide inhibitors of transforming growth factor-β enhance the efficacy of antitumor immunotherapy

    International Journal of Cancer, Vol. 125, Núm. 11, pp. 2614-2623

2008

  1. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects

    Cancer Immunology, Immunotherapy, Vol. 57, Núm. 1, pp. 19-29

  2. In vitro and in vivo down-regulation of regulatory T cell activity with a peptide inhibitor of TGF-β1

    Journal of Immunology, Vol. 181, Núm. 1, pp. 126-135

  3. Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein

    Molecular Therapy, Vol. 16, Núm. 1, pp. 210-217

2007

  1. Induction of potent and long-lasting CD4 and CD8 T-cell responses against hepatitis C virus by immunization with viral antigens plus poly(I:C) and anti-CD40

    Antiviral Research, Vol. 74, Núm. 1, pp. 25-35

  2. The extra domain A from fibronectin targets antigens to TLR4-expressing cells and induces cytotoxic T cell responses in vivo

    Journal of Immunology, Vol. 178, Núm. 2, pp. 748-756